August 14, 2020
2 min read
The study was funded by a grant from the National Cancer Institute as part of the Cancer Intervention and Surveillance Modeling Network (CISNET).
Epigenomics AG found most patients prefer the Epi proColon blood test for colorectal cancer screening vs. fecal immunochemical tests and colonoscopy screening, according to a report published in Journal of the National Cancer Institute.
Healio Gastroenterology spoke with Greg Hamilton, CEO of Epigenomics AG, to discuss the study results and next steps.
Healio: What was the purpose and design of the study?
Hamilton: The purpose was to determine which of the available alternatives to FIT and colonoscopy is the most promising from a cost-effectiveness perspective.
Investigators used the cancer intervention and surveillance modeling network-microsimulation screening analysis (CISNET-MISCAN) colon model to evaluate the cost effectiveness of the following methods:
- CT Colonography every 5 or 10 years;
- Multi-targeted stool DNA (mtSNDA; Cologuard) every 1 or 3 years;
- Methylated Sept9 DNA (mSEPT9; epi proColon) every 1 or 2 years; and
- PillCam every 5 or 10 years.
The MISCAN model was developed by the Department of Public Health within the Erasmus University Medical Center, Rotterdam, the Netherlands. It is part of the U.S. National Cancer Institute’s CISNET and has been used to inform colon cancer screening recommendations such as the United States Preventative Services Task Force and the American Cancer Society.
Healio: What were the results of the study?
Hamilton: Study results suggest that for individuals not willing to participate in FIT or colonoscopy screening, mSEPT9 is the test of choice if the high colonoscopy referral rate is acceptable to them.
Additionally, investigators found annual mSEPT9 testing was clinically more effective (reduction in incidence and mortality of colon cancer) than mtSNDA every three years and annual FIT testing.
Healio: What was the take-home message?
Hamilton: mSEPT9 is the “test of choice” for patients who are unwilling to participate in FIT or colonoscopy screening based on its clinical performance and cost effectiveness.
Healio: What was the conclusion?
Healio: mSEPT9 is an FDA approved colon cancer screening test that is highly effective and cost efficient. Medicare is currently evaluating coverage of mSEPT9 and their preliminary decision will be released in approximately 2 weeks. Based on the significant amount of evidence including this recent Journal of the National Cancer Institute publication, we believe CMS will issue a positive coverage decision for mSEPT9. This means that by then end of November, Medicare patients who don’t participate in FIT or colonoscopy screening will have the opportunity to take the only FDA-approved blood test for CRC screening, epi proColon (assuming a positive coverage decision). Considering there are millions of unscreened Medicare patients, this new technology has the potential to save hundreds of thousands of lives.
Healio: What is the next step in research?
Hamilton: As part of epi proColon’s FDA premarket approval, the company is conducting a “post approval study” (PAS). PAS studies are required for all premarket approval application approved products. This is a longitudinal study that will verify the long-term performance of the test. The study is expected to be completed within the next 2 to 3 years.